Amid a growing number of probes into the pharmaceutical industry, Mallinckrodt (MNK) tentatively agreed to pay $15.4 million to settle charges of illegal marketing by Questcor, a company that it purchased five years ago and was infamous for dramatically raising the price of a treatment for infantile spasms.

At the same time, however, the drug maker vowed to fight new claims by the Department of Justice that Questcor illegally used a charity to pay kickbacks aimed at encouraging Medicare patients to use the pricey medicine, which is known as Acthar Gel.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy